Amgen’s Immunotherapy for Lung Cancer Reduces Disease Progression by 34%
- Results from the Phase III CodeBreaK 200 clinical trial found that Amgen’s targeted therapy Lumakras successfully extended progression-free survival (PFS) by about two months and was 15% more effective at extending PFS to one year when compared to docetaxel chemotherapy. During the trial, patients taking Lumakras suffered fewer...
